← Evidence map

ArticleHaematologica2026

Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study.

Thomas Chalopin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Assessing the benefit of incorporating an anti-CD38 monoclonal antibody into second- or third-line systemic treatment for patients with relapsed/refractory multiple myeloma: results from the French real-world EMMY study. | OpenQuestion